Share on StockTwits

WuXi PharmaTech (NYSE:WX) is scheduled to be issuing its Q214 quarterly earnings data on Wednesday, August 13th. Analysts expect the company to announce earnings of $0.47 per share and revenue of $162.11 million for the quarter. WuXi PharmaTech has set its Q2 guidance at $0.46-0.48 EPS and its FY14 guidance at $1.80-1.85 EPS.Parties that are interested in participating in the company’s conference call can do so using this link.

WuXi PharmaTech (NYSE:WX) last issued its quarterly earnings data on Wednesday, May 14th. The company reported $0.30 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.39 by $0.09. The company had revenue of $146.70 million for the quarter, compared to the consensus estimate of $145.00 million. During the same quarter in the prior year, the company posted $0.35 earnings per share. The company’s quarterly revenue was up 11.2% on a year-over-year basis. On average, analysts expect WuXi PharmaTech to post $1.84 EPS for the current fiscal year and $2.17 EPS for the next fiscal year.

Shares of WuXi PharmaTech (NYSE:WX) opened at 32.36 on Tuesday. WuXi PharmaTech has a 1-year low of $23.48 and a 1-year high of $40.72. The stock’s 50-day moving average is $32.67 and its 200-day moving average is $34.66. The company has a market cap of $2.311 billion and a price-to-earnings ratio of 21.28.

Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of WuXi PharmaTech from an “underperform” rating to a “neutral” rating in a research note on Wednesday, July 16th. They now have a $33.50 price target on the stock. Analysts at Morgan Stanley reiterated an “overweight” rating on shares of WuXi PharmaTech in a research note on Thursday, May 15th. They now have a $45.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. WuXi PharmaTech has an average rating of “Buy” and a consensus target price of $37.90.

WuXi PharmaTech (NYSE:WX) Inc, (WuXi) is a pharmaceutical, biotechnology and medical device research and development (R&D) outsourcing company, with operations in People’s Republic of China and the United States.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.